ImageneBio, Inc.

IMA Nasdaq CIK: 0001835579

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 12526 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
Mailing Address 12526 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
Phone 857-343-8292
Fiscal Year End 1231
EIN 811697316

Financial Overview

FY2025

$133.14M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 18, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
10-K Annual financial report March 10, 2026 View on SEC
3 Initial insider ownership report February 20, 2026 View on SEC
8-K Current report of material events February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 12, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) January 6, 2026 View on SEC
4 Insider stock transaction report January 2, 2026 View on SEC

Annual Reports

10-K March 10, 2026
  • Strategic merger of Ikena Oncology and Inmagene Biopharmaceuticals created ImageneBio, poised for innovation.
  • Lead candidate IMG-007 is in Phase 2 clinical trials for atopic dermatitis and asthma, with promising early data.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.